Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort

Respirology

Volumn 22, Issue 7, 2017, Pages 1386-1392

  Lammi, Matthew R ^a   Saketkoo, Lesley A ^b   Gordon, Jessica K ^c   Lauto, Paula ^a   Fagan, Karen ^d   Steen, Virginia D ^e  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

diastolic dysfunction; pulmonary hypertension; scleroderma; systemic sclerosis; treatment

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PROSTANOID;

ADULT; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RISK; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RISK ASSESSMENT; SIX MINUTE WALK TEST; SURVIVAL ANALYSIS; SURVIVAL PREDICTION; SYSTEMIC SCLEROSIS; TASK PERFORMANCE; CLINICAL TRIAL; COMPLICATION; DISEASE EXACERBATION; HOSPITALIZATION; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CARDIAC CATHETERIZATION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; SCLERODERMA, SYSTEMIC; SURVIVAL ANALYSIS;

EID: 85018928505     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.13067     Document Type: Article

References (31)

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62: D34–41.
2. Ciurzynski MBP, Lichodziejewska B, Szewczyk A, Glinska-Wielochowska M, Jankowski K, Kurnicka K, Kurzyna M, Glinski W, Pruszcyk P. Assessment of left and right ventricular diastolic function in patients with systemic sclerosis. Kardiol. Pol. 2008; 66: 269–76.
3. Vachiery JL, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs JS et al. Pulmonary hypertension due to left heart diseases. J. Am. Coll. Cardiol. 2013; 62: D100–8.
4. Hinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J. Rheumatol. 2011; 38: 2172–9.
5. Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, Eisenberg MJ, Joyal D, Hudson M, Boutet K et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur. Respir. J. 2013; 42: 1083–91.
6. Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, Maurer G, Lang IM. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest 2013; 143: 758–66.
7. Naeije R. Physiology of the pulmonary circulation and the right heart. Curr. Hypertens. Res. 2013; 15: 623–31.
8. Hair JF Jr, Anderson RE, Tatham RL, Black WC. Multivariate Data Analysis. New York, Macmillan Publishing Company, 1995.
9. Lammi MRSL, Gordon JK, Lauto P, Steen VD. Scleroderma patients with pulmonary hypertension and increased pulmonary capillary wedge pressure in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort. Am. J. Respir. Crit. Care Med. 2014; 189: A4771.
10. Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, Hatron PY, Beregi JP, Hachulla E. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann. Rheum. Dis. 2009; 68: 1878–84.
11. Poanta L, Dadu R, Tiboc C, Rednic S, Dumitrascu D. Systolic and diastolic function in patients with systemic sclerosis. Eur. J. Intern. Med. 2009; 20: 378–82.
12. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, Riemekasten G, Cozzi F, Beretta L, Derk CT et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann. Rheum. Dis. 2010; 69: 218–21.
13. Ciurzynski M, Bienias P, Irzyk K, Kostrubiec M, Szewczyk A, Demkow U, Siwicka M, Kurnicka K, Lichodziejewska B, Pruszczyk P. Heart diastolic dysfunction in patients with systemic sclerosis. Arch. Med. Sci. 2014; 10: 445–54.
14. Akdogan A, Kaya EB, Sahin A, Okutucu S, Yakut E, Kalyoncu U, Aksoy H, Karadag O, Calguneri M, Tokgozoglu L et al. Relationship between left ventricular diastolic dysfunction and six minute walk test in patients with systemic sclerosis. Int. J. Rheum. Dis. 2011; 14: 379–83.
15. Faludi R, Kolto G, Bartos B, Csima G, Czirjak L, Komocsi A. Five-year follow-up of left ventricular diastolic function in systemic sclerosis patients: determinants of mortality and disease progression. Semin. Arthritis Rheum. 2014; 44: 220–7.
16. Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, Guillevin L, Kahan A, Allanore Y. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum. 2008; 58: 1803–9.
17. Hinchcliff M, Desai CS, Varga J, Shah SJ. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin. Exp. Rheumatol. 2012; 30: S30–7.
18. Plazak W, Gryga K, Sznajd J, Tomkiewicz-Pajak L, Suchon E, Wilisowska J, Musial J, Podolec P. Diastolic heart dysfunction, increased pulmonary capillary wedge pressure and impaired exercise tolerance in patients with systemic sclerosis. Kardiol. Pol. 2011; 69: 243–9.
19. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J. Am. Coll. Cardiol. 2009; 53: 1119–26.
20. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, Rich S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ. Heart Fail. 2011; 4: 257–65.
21. Gordon JK, Szymonifka J, Lammi MR, Steen VD. Clinical characterization of patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma cohort [abstract]. Arthritis Rheumatol. 2016; 68(Suppl. 10): 973.
22. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 2000; 161: 487–92.
23. Schoindre Y, Meune C, Dinh-Xuan AT, Avouac J, Kahan A, Allanore Y. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J. Rheumatol. 2009; 36: 1481–5.
24. Deuschle K, Weinert K, Becker MO, Backhaus M, Huscher D, Riemekasten G. Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis. Clin. Exp. Rheumatol. 2011; 29: S53–9.
25. Sanges S, Launay D, Rhee RL, Sitbon O, Hachulla E, Mouthon L, Guillevin L, Rottat L, Montani D, De Groote P et al. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naive systemic sclerosis-associated pulmonary arterial hypertension. Ann. Rheum. Dis. 2016; 75: 1457–65.
26. Wilsher M, Good N, Hopkins R, Young P, Milne D, Gibson A, Suppiah R, Ly J, Doughty R, Dalbeth N. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology 2012; 17: 647–52.
27. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 347–54.
28. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levnie B et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Card. Fail. 2005; 11: 12–20.
29. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 1997; 134: 44–54.
30. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343–9.
31. Tampakakis E, Tedford RJ. Reply: characterization of pulmonary hypertension in heart failure using the diastolic pressure gradient: the conundrum of high and low diastolic pulmonary gradient. JACC Heart Fail. 2015; 3: 426–7.